Posts Tagged ‘Hydrocodone containing products’
North Carolina STOP Act Looks to Address the Opioid Crisis
North Carolina’s Strengthen Opioid Misuse Prevention Act (STOP Act) sets limits on certain ‘targeted controlled substance” prescriptions for acute and post surgical pain and seeks to address the opioid abuse epidemic in North Carolina by changing the way certain controlled substances are prescribed. According the the STOP Act, practitioners, including physician assistants and nurse practitioners,…
Read MoreFDA Revises Labeling to Limit Pediatric Use of Opioid Cough and Cold Medicines
Today, the FDA announced that it is requiring safety labeling changes to limit the use of prescription opioid cough and cold medicines containing codeine or hydrocodone in children younger than 18 years old. Once the labeling changes are made, these products will not be indicated to treat cough in any pediatric population and will be…
Read MorePharmacists Must Ensure Prescription Orders are Issued for a Legitimate Medical Purpose by an Authorized Prescriber and Have a Recognized Medical Utility or Application
As discussed previously on the Baer Law Blog, corresponding responsibility remains one of the most misunderstood or unknown concepts found in the Drug Enforcement Administration’s (DEA) regulations. The DEA’s regulations (21 CFR 1306.04) regarding corresponding responsibility state: A prescription for a controlled substance to be effective must be issued for a legitimate medical purpose by an…
Read MoreCountdown to October 6, 2014: Hydrocodone Containing Product Reclassification
As discussed previously here on the Baer Law Blog, after more than a decade of debate, hydrocodone containing products (HCPs) are being reclassified from Schedule III to the more restrictive Schedule II controlled substances category starting October 6, 2014. HCPs are the most prescribed drug in the United States, second only to levothyroxine, a thyroid…
Read More